Breaking Down Yunnan Botanee Bio-Technology Group Co.LTD Financial Health: Key Insights for Investors

Yunnan Botanee Bio-Technology Group's recent figures paint a complex picture for investors: operating revenue in 2024 was CNY 5.74 billion (up just 0.15% year-on-year) after growth deceleration from +24.65% in 2022 to +14.23% in 2023, while H1 2025 revenue rebounded with an 18.45% year-on-year increase to CNY 2.805 billion; profitability remains moderate with a net profit margin of 8.8% and ROE of 5.97% but operating margin only 2.21% and ROA 1.50%, and H1 2025 net income plunged 49% to CNY 246.66 million; balance-sheet indicators show conservative leverage (debt-to-equity 0.13), total assets up 10.61% to CNY 8.30 billion, enterprise value at CNY 15.25 billion and a market cap collapse of -75.29% since March 2021 to CNY 17.05 billion, while liquidity looks strong with a current ratio of 3.64 and quick ratio 3.00 despite a 16.45% drop in cash to CNY 1.81 billion and a 41.3% rise in accounts receivable to CNY 1.05 billion; valuation metrics include a trailing P/E of 51.08, forward P/E 26.14, P/S 3.52 and EV/EBITDA 40.17, and risks - from rising marketing and personnel costs to impairment provisions and volatile consumer demand - sit alongside growth levers such as OMO channel expansion, 2.707 million registered users on the self-built platform, CNY 181.73 million from the Viennona counter service (≈6.51% of main income) and OTC distribution sales of CNY 3.547 billion (≈12.71% of main income, +20.01% YoY); which of these data points will shape investor decisions?

Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ) - Revenue Analysis

• Revenue per employee ≈ CNY 1.31 million, indicating moderate productivity given industry labor intensity.
• Market capitalization fell from CNY 68.97 billion (Mar 2021) to CNY 17.05 billion (Dec 2025), a decline of 75.29% over four years.
• Trailing P/S ratio: 3.52 - the stock trades at a moderate premium relative to sales.

Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ) - Profitability Metrics

Key profitability indicators for Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ) show moderate margin performance with pressure on earnings in recent periods. The following metrics summarize the company's profitability profile and short-term earnings trajectory.

• Net profit margin (2024): 8.8% - indicates moderate profitability after operating costs and market pressures.
• Return on equity (ROE): 5.97% - the company's ability to generate profit from shareholders' equity.
• Operating margin: 2.21% - a small portion of revenue retained after operating expenses.
• Return on assets (ROA): 1.50% - efficiency of asset utilization in producing profit.
• Return on invested capital (ROIC): 1.74% - effectiveness of capital investments in generating returns.
• Net income (H1 2025): CNY 246.66 million - down 49% year-over-year versus H1 2024.

For broader context on the company's background, ownership and business model, see: Yunnan Botanee Bio-Technology Group Co.LTD: History, Ownership, Mission, How It Works & Makes Money

Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ) - Debt vs. Equity Structure

• Debt-to-equity ratio: 0.13 - a conservative leverage position.
• Total assets (2024): CNY 8.30 billion - +10.61% year-over-year.
• Net assets attributable to shareholders (2024): CNY 6.05 billion - +3.22% year-over-year.
• Enterprise value: CNY 15.25 billion - reflects combined market cap and net debt.
• Market capitalization trajectory: declined 75.29% over four years (CNY 68.97bn in Mar 2021 → CNY 17.05bn in Dec 2025).
• Total liabilities and shareholders' equity: relatively stable over the past three years, implying consistent financial structure.

• The low debt-to-equity ratio reduces default and interest-rate risks, supporting resilience during cyclical downturns.
• Asset growth of 10.61% in 2024 indicates ongoing investment or balance-sheet expansion, while shareholder equity growth (3.22%) shows modest value retention for owners.
• A sharp decline in market capitalization (-75.29%) materially compresses market-implied valuation relative to historical levels; enterprise value of CNY 15.25bn shows the market values the company lower than prior peaks even after accounting for debt.
• Stability in liabilities and equity over three years suggests management has maintained financial policies without aggressive recapitalization or debt accumulation.

Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ) - Liquidity and Solvency

• Current ratio: 3.64 - strong short-term coverage of liabilities by current assets.
• Quick ratio: 3.00 - sufficient immediate liquidity excluding inventory.
• Interest coverage ratio: 11.52 - healthy ability to service interest expense.
• Cash & cash equivalents (2024): CNY 1.81 billion - a 16.45% decrease year-over-year.
• Accounts receivable (2024): CNY 1.05 billion - a 41.3% increase year-over-year; potential pressure on near-term liquidity.
• Operating cash flow significantly exceeded net income in 2024, indicating efficient cash conversion and resilient underlying operations.

• High current and quick ratios provide a buffer, but the CNY 1.81 billion cash decline and CNY 1.05 billion receivables build warrant monitoring of working capital trends.
• Interest coverage of 11.52 reduces near-term refinancing risk, supporting solvency even if cash balances fluctuate.
• Persistent receivables growth may require tighter collections or alternative liquidity measures despite robust operating cash generation.

Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ) - Valuation Analysis

• Trailing P/E: 51.08 - indicates investors are paying CNY 51.08 for each CNY 1 of last-twelve-months earnings.
• Forward P/E: 26.14 - market-implied earnings improvement, roughly a 49% decline from trailing P/E, reflecting anticipated profit growth or margin expansion.
• Price-to-Book (P/B): 2.93 - market values net assets at nearly 3x book value.
• EV/EBITDA: 40.17 - a very elevated multiple suggesting limited current EBITDA backing relative to enterprise value.

Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ) - Risk Factors

• Heightened market competition has forced higher marketing spend and promotional activity, putting downward pressure on gross margins and operating profit.
• Volatility in consumer demand - particularly during large online promotional events - creates sales unpredictability and inventory/working-capital management risk.
• Management has recorded provisions for long‑term asset impairment related to unmet investment commitments, which can erode equity and reduce future earnings capacity.
• Rising personnel costs and increasing depreciation & amortization expenses are compressing operating margins and return on invested capital.
• Average customer acquisition cost (CAC) for the company's main online self-operated stores has increased, lowering marketing efficiency and raising payback periods on digital spend.
• Investor sentiment has weakened: market capitalization fell from CNY 68.97 billion (March 2021) to CNY 17.05 billion (December 2025), a decline of 75.29%, reflecting heightened market concerns and valuation risk.

• Liquidity & capital structure: impairment provisions reduce net asset cushions and could lead to tighter borrowing terms or higher financing costs if negative trends persist.
• Profitability sensitivity: with elevated marketing and personnel costs, small revenue declines or margin erosion can disproportionately reduce net profit.
• Execution risk: failure to translate higher online investment into sustainable customer lifetime value will magnify CAC impact and impair ROIC.
• Market sentiment risk: the sharp market-cap decline indicates potential for higher share-price volatility and diluted investor confidence in near to medium term.

Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ) - Growth Opportunities

• Strategic focus on brand development, product innovation, and multi-channel expansion to sustain and accelerate revenue growth.
• Investment in digital tools (Internet, AI) to optimize R&D, marketing personalization, demand forecasting, and supply-chain efficiency.
• OMO (Online-Merge-Offline) cross-border marketing strategies designed to deepen market penetration and improve consumer engagement across geographies.

Key channel- and platform-level performance indicators highlight current traction and near-term scalability:

• Self-built "Viennona counter service platform" store: operating income CNY 181.73 million, ≈6.51% of main business income.
• Self-built OMO channel online sales platform: ~2.707 million registered users, with ~122,800 new registered users during the reporting period.
• OTC distribution channel sales model: operating income CNY 3.547 billion, ≈12.71% of main business income, year-on-year increase ≈20.01%.

• Growth levers: scale OMO platforms to convert registered users into higher ARPU, expand AI-driven personalized marketing, and deepen pharmacy & OTC distribution penetration.
• Risks to monitor: customer acquisition cost on digital channels, margin pressure from channel incentives, and cross-border regulatory complexity for OMO internationalization.

For institutional positioning, investor messaging, and how these initiatives tie to corporate purpose, see: Mission Statement, Vision, & Core Values (2026) of Yunnan Botanee Bio-Technology Group Co.LTD.